Text: No. According to this QALY analysis, the payer should not pay for the new drug given that the standard per QALY has an upper limit of $100,000. The new treatment is only allowing the patient an additional 3 months of expected life at a cost that is well over the $100,000 per quality-adjusted year limit (with only a small increase of 0.1 in quality level from 0.3 to 0.4).